Phase II Study of Pembrolizumab in Combination With Binimetinib and Bevacizumab in Patients With Refractory Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Nov 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Binimetinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 15 Nov 2019 Planned End Date changed from 31 Aug 2019 to 31 Dec 2021.
- 15 Nov 2019 Planned primary completion date changed from 31 Aug 2019 to 31 Dec 2020.
- 02 Nov 2018 Status changed from not yet recruiting to recruiting.